Pascal Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSCBF research report →
About the company
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy.
- CEO
- John Kueber
- IPO
- 2015
- Employees
- 2
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $4.20M
- P/E
- -5.92
- P/S
- 0.68
- P/B
- 1.19
- EV/EBITDA
- -42.70
- Div Yield
- 0.00%
- Gross Margin
- 41.28%
- Op Margin
- -16.96%
- Net Margin
- -16.21%
- ROE
- -23.66%
- ROIC
- -23.72%
- Revenue
- $670.16K · 0.00%
- Net Income
- $-398,945.11 · 17.35%
- EPS
- $-0.02 · 54.05%
- Op Income
- $-895,844.9
- FCF YoY
- -162.53%
- 52W High
- $0.15
- 52W Low
- $0.02
- 50D MA
- $0.10
- 200D MA
- $0.09
- Beta
- -0.01
- Avg Volume
- 20.43K
Get TickerSpark's AI analysis on PSCBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PSCBF coverage
Recent articles, reports, and earnings notes.
No research on PSCBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSCBF report →Similar companies
Peers in the same neighborhood.